268 related articles for article (PubMed ID: 22334770)
1. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Banerjee S; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():43-55. PubMed ID: 22334768
[TBL] [Abstract][Full Text] [Related]
3. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
Doherty DE; Tashkin DP; Kerwin E; Knorr BA; Shekar T; Banerjee S; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
Kosoglou T; Hubbell J; Xuan F; Cutler DL; Meehan AG; Kantesaria B; Wittmer BA
Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
[TBL] [Abstract][Full Text] [Related]
6. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
Maspero JF; Nolte H; Chérrez-Ojeda I;
J Asthma; 2010 Dec; 47(10):1106-15. PubMed ID: 20874458
[TBL] [Abstract][Full Text] [Related]
8. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function.
Meltzer EO; Kuna P; Nolte H; Nayak AS; Laforce C;
Eur Respir J; 2012 Feb; 39(2):279-89. PubMed ID: 21828036
[TBL] [Abstract][Full Text] [Related]
9. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.
Weinstein SF; Corren J; Murphy K; Nolte H; White M;
Allergy Asthma Proc; 2010; 31(4):280-9. PubMed ID: 20687982
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
Nolte H; Pavord I; Backer V; Spector S; Shekar T; Gates D; Nair P; Hargreave F
Respir Med; 2013 May; 107(5):656-64. PubMed ID: 23490226
[TBL] [Abstract][Full Text] [Related]
11. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids.
Nathan RA; Nolte H; Pearlman DS;
Allergy Asthma Proc; 2010; 31(4):269-79. PubMed ID: 20678306
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
Rennard SI; Tashkin DP; McElhattan J; Goldman M; Ramachandran S; Martin UJ; Silkoff PE
Drugs; 2009; 69(5):549-65. PubMed ID: 19368417
[TBL] [Abstract][Full Text] [Related]
15. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma.
Maspero J; Cherrez I; Doherty DE; Tashkin DP; Kuna P; Kuo WL; Gates D; Nolte H; Chylack LT
Respir Med; 2014 Sep; 108(9):1355-62. PubMed ID: 25044280
[TBL] [Abstract][Full Text] [Related]
16. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
17. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
18. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
Lipworth BJ; Collier DJ; Gon Y; Zhong N; Nishi K; Chen R; Arora S; Maes A; Siddiqui S; Reisner C; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():2969-2984. PubMed ID: 30310273
[TBL] [Abstract][Full Text] [Related]
19. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Koch A; Pizzichini E; Hamilton A; Hart L; Korducki L; De Salvo MC; Paggiaro P
Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
[TBL] [Abstract][Full Text] [Related]
20. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
